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Abstract: Attention-deﬁ  cit/hyperactivity disorder (ADHD) affects a large number of children. 
For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. 
Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-
(R,R)-MPH, was recently introduced as another potential option in the stimulant class of 
medications. This paper reviews and summarizes the available research literature on d-MPH 
regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, 
and clinical perspectives. d-MPH potentially may offer some advantages in the realms of 
absorption and duration of action compared with its racemic counterpart. The differences in 
pharmacokinetics and clinical implications of the immediate-release and extended-release forms 
of d-MPH are also compared and contrasted.
Keywords: ADHD, dexmethylphenidate, chemistry, receptor binding, toxicology, 
pharmacokinetics
Brief history
Attention-deﬁ  cit/hyperactivity disorder (ADHD) affects a large number of children. 
In the United States, rates range from 5% to 6% of school-age children (Guevara et al 
2002; Lesesne et al 2003).The illness is characterized by a triad of symptom clusters 
which include inattention, hyperactivity, and impulsivity. Usually the illness is ﬁ  rst 
detected during the early school years (Goldman et al 1998), but can persist during 
adolescence and even adulthood. If left untreated, ADHD can be associated with a 
number of poor outcomes including academic failure, delinquency, and problems 
with substance abuse (Barkley 1990; Biederman et al 1996; Dulcan 1997; Wilens 
et al 2004).
Stimulants have been the mainstay of pharmacological treatment of ADHD for 
over 60 years. Their effect on disruptive behavior was discovered in 1937, when these 
drugs proved to increase compliance, improve academic performance, and reduce 
motor activity in hyperactive children (Bradley 1937). Methylphenidate (MPH) is the 
most frequently prescribed among stimulant agents. It has proven efﬁ  cacy on ADHD 
symptoms (Kimko et al 1999; Greenhill et al 2002).
d-MPH vs d,l-MPH (racemic MPH)
Until the introduction of the d-MPH (d-threo-(R,R)-MPH, d-MPH) in 2002, all 
clinically used MPH formulations contained a racemic (1:1) mixture of d-threo-(R,R)-
MPH and l-threo-(R,R)-MPH isomers (Figure 1). The development of d-MPH was 
based on the ﬁ  ndings that similar improvement on sustained attention was achieved 
after treatment with d-equivalent doses of d-MPH and d,l-MPH, but not after l-MPH 
(Srinivas et al 1992). It was found that clinical efﬁ  cacy was highly correlated with Neuropsychiatric Disease and Treatment 2006:2(4) 468
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plasma concentrations of d-MPH. The elimination of the 
l-isomer does not diminish the efﬁ  cacy of an acute dose 
of MPH (Quinn et al 2004). The efﬁ  cacy of the d-isomer 
was equivalent to the racemic preparation in ameliorating 
the target symptoms of ADHD and increasing academic 
productivity. Thus, it was thought that the efﬁ  cacy of MPH 
resides in the d-isomer (Lim et al 1986; Patrick et al 1987; 
Srinivas et al 1987, 1992). Other research demonstrated 
that besides clinical effectiveness, the undesired pressor 
and anorexic actions of d,l-MPH also appear to reside in the 
d-isomer (Srinivas et al 1992; Anonymous 2002; Schefﬂ  er 
et al 2003; Teo et al 2004).
d-MPH not only appears to be the more active of the two 
enantiomers, but also better absorbed; plasma concentrations 
of d-MPH are many times higher than the l-enantiomer 
after oral dosing of racemic MPH (Hubbard et al 1989; 
Ding et al 1997; Kimko et al 1999; Modi et al 2000) or 
intravenous administration (Kimko et al 1999). This is 
seen with both immediate-release (Kimko et al 1999) and 
sustained-released (Hubbard et al 1989; Kimko et al 1999) 
forms of racemic MPH. The pre-systemic metabolism and 
metabolic clearance of d,l-MPH is also an enantioselective 
process which, too, contributes to markedly higher plasma 
concentrations of d-MPH relative to l-MPH (Markowitz 
et al 2003; Patrick et al 2005). It was also found that equi-
molar doses of d-MPH yielded similar pharmacokinetics as 
those noted with administration of the d,l-racemic mixture 
(Srinivas et al 1992).
As a result, the d-MPH product was developed, and 
approved by the FDA for clinical use on August 31 2001. 
The d-MPH product appears to double the therapeutic 
potency of the racemic d,l-MPH; when only half dose 
of racemic d,l-MPH was used, d-MPH produced similar 
pharmacokinetic parameters (Cmax, Tmax, and half-life) 
(Anonymous 2002; Keating and Figgitt 2002; Markowitz 
et al 2003). The administration of d-MPH with food has no 
signiﬁ  cant effect on bioavailability, but with racemic MPH, 
Tmax was delayed by 1 hour (Teo et al 2004). In addition, 
a number of studies (Patrick et al 1981; Arnold et al 2004; 
Quinn et al 2004; Silva et al 2004; Wigal et al 2004) sug-
gested that d-MPH might have a longer duration of action 
than d,l-MPH on tests measuring attention, hyperactivity, 
and impulsivity. However, this requires further controlled 
study. As mentioned before, the use of d-MPH in ADHD 
allows the administration of lower doses than those currently 
prescribed with d,l-MPH.
Chemistry
Molecules that are non-superimposable mirror images of one 
another are termed enantiomers and when equal amounts 
(1:1) of enantiomeric molecules are present together, the 
product is termed racemic. Most current commercial formu-
lations of MPH consist of the racemic mixture of the threo 
pair of MPH isomers (d,l-threo MPH).
Although MPH has two chiral centers, and therefore 
four isomers, a d,l-erythro-MPH pair and a d,l-threo-MPH 
pair, only the racemic mixture of the threo pair of enantio-
mers (d,l-threo-MPH) is used therapeutically. This is due 
to the recognition that it has fewer side-effects than the 
erythro enantiomers. Figure 1 shows the chemical struc-
tures of d- and l-threo-MPH. It should be noted that the 
phenethylamine moiety of d-MPH is shared by dopamine 
Figure 1 Chemical structures of d- and l-threo-methylphenidate.
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and norepinephrine. It is the phenethylamine structure that 
provides the transporter receptor afﬁ  nity and it competes 
with dopamine for binding (Kimko et al 1999).
The predominant metabolic pathway of MPH is 
de-esterification to form pharmacologically inactive 
d- or l-ritalinice acid by the carboxyesterase-I isoform, 
CES1A1 (Sun et al 2004). It was shown that d,l-threo-
methylphenidate was stereoselectively metabolized in 
humans (Lim et al 1986; Srinivas et al 1987), with l-threo-
MPH being eliminated faster than d-threo-MPH (Srinivas 
et al 1992; Sun et al 2004). In a double-blind, four-way, 
randomized, crossover study, l-MPH showed no differ-
ence vs placebo in improving the sustained attention in 
humans. Moreover, a 5-mg dose of d-threo-MPH has the 
same attention improvement effect as a 10-mg dose of 
d,l-threo-MPH racemic mixture. Hence, the clinical effect 
of MPH is attributed to the d-enantiomer (Srinivas et al 
1992). The brand name for d-MPH is Focalin®.In terms of 
its chemical composition, d-MPH hydrochloride is methyl 
α-phenyl-2-piperidineacetate hydrochloride, (R,R´)-(+)-. 
Its empirical formula is C14H19NO2•HCl. Its molecular 
weight is 269.77.
Binding and imaging studies of 
d-isomer vs l-isomer: from animals 
to humans
Although its mechanism is poorly understood, pharmaco-
dynamic studies have suggested that the therapeutic effect 
of MPH in the treatment of ADHD appears to lie primar-
ily in increasing the synaptic concentration of dopamine 
by blocking dopamine transporters (DAT) (Gatley et al 
1996; Ding et al 1997; Davids et al 2002), as well as in 
blocking norepinephrine transporters. This is in agreement 
with recent reports that there is signiﬁ  cantly increased 
expression of DAT in ADHD patients (Volkow et al 2002) 
and the effects of MPH administration is associated with 
a decrease in DAT receptor concentration in the striatum 
(Krause et al 2000).
Normally, DAT decreases with age (Volkow et al 1996). 
However, in methamphetamine abusers, the number of DAT 
also are reduced (Volkow et al 2001a, 2001b). Recovery of 
DAT receptors is evident with protracted abstinence (Volkow 
et al 2001a). The binding of d-MPH to DAT in the striatum 
is reduced by cocaine in a dose-dependent manner (Fowler 
et al 1998).
Studies in humans, baboons, and rats seem to indicate 
that the pharmacological specificity of MPH resides 
predominantly in its d-isomer (Srinivas et al 1992; 
Ding et al 1997; Anonymous 2002). Thus, in vivo binding 
measures of radiolabeled d-MPH to dopamine transporter 
in the brain with positron emission tomography (PET) or 
microdialysis have not only become a valuable technique 
to analyze pharmacodynamics of MPH and its enantiomers 
(Ding et al 1995, 1997, 2004; Gatley et al 1995; Logan et al 
1996, 2001; Volkow et al 2002; Kilbourn 2004), but also 
served as an effective tool to assess expression or density 
of dopamine transporters in tissues of humans and animals 
(Volkow et al 1995, 1996b, 2001a, 2001b; Fowler et al 1998; 
Gatley et al 1999).
PET studies provide a quantitative measure of distribu-
tion volume ratios, which represent speciﬁ  c radioligand 
binding (Volkow et al 1995; Wang et al 1995). Measures 
of distribution volume ratios are based upon the following 
assumptions: (i) Even if the plasma concentration of the 
radiolabeled tracer is unknown (for example, without blood 
samples from patients), “non-invasive” quantiﬁ  cation is 
still possible using a reference region with graphical analy-
sis (Logan et al 1996); (ii) for neuroreceptor–transporter 
modeling, no specific binding occurs in the reference 
region (Volkow et al 2002); (iii) the distribution volume 
of the reference region is the same as the distribution vol-
ume of the ﬁ  rst compartment (free and non-speciﬁ  cally 
bound tracer) in the target region. Since the basal ganglia 
of striatum expresses more dopamine transporters (DAT), 
it is considered as the target region for d-MPH, while the 
cerebellum does not express DAT, so it usually is considered 
the reference region (Volkow et al 2002; Kilbourn 2004). 
Thus, the tissue distribution volume ratio of [11C]d-MPH 
in the basal ganglia containing the speciﬁ  c binding to that 
in the cerebellum which demonstrates non-speciﬁ  c binding 
should be considered to be a reﬂ  ection of dopamine trans-
porter availability.
Recent results from PET and other imaging studies for 
the two enantiomers of racemic MPH demonstrated that 
[11C]d-MPH bound to the dopamine transporter in the basal 
ganglia is highly speciﬁ  c and reproducible (Ding et al 1997). 
However, there is no evidence of regional speciﬁ  c binding for 
[11C]l-threo-MPH in the brain. These results suggest that the 
binding of MPH to DAT in the striatum is enantiospeciﬁ  c. 
These data are also in agreement with those from basic and 
clinical studies showing that d-MPH at therapeutic doses 
exerts much stronger effects than racemic MPH or l-threo-
MPH on extracellular dopamine in rats and on improvement 
in sustained attention in children (Srinivas et al 1992; Patrick 
et al 1987).Neuropsychiatric Disease and Treatment 2006:2(4) 470
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Moreover, d- and l-MPH also undergo enantioselective 
metabolism (Srinivas et al 1987; Hubbard et al 1989; 
Anonymous 2002; Sun et al 2004), as evidenced by the 
following ﬁ  ndings. First, as mentioned before, because of 
rapid pre-systemic metabolism, orally administered l-threo-
MPH is poorly absorbed in humans. Thus, the absolute 
bioavailability of d-MPH is signiﬁ  cantly greater than that of 
l-threo-MPH (Srinivas et al 1993; Sun et al 2004). Second, 
because there is a correlation between plasma concentra-
tions and DAT occupancy, the plasma concentration could 
serve as an indicator for DAT binding (Srinivas et al 1992). 
However, DAT binding by d-MPH could also be obtained 
from calculated tissue distribution volume without patients’ 
blood samples (Logan et al 1996). Third, while the rate of 
brain uptake for both enantiomers was not signiﬁ  cantly dif-
ferent, the rate of clearance after 1.5 hours from the brain 
or plasma was much slower for d-MPH than that of l-threo-
MPH (Volkow et al 2002). Fourth, greater than 50% DAT 
binding in the basal ganglia by d-MPH may be required for 
therapeutic efﬁ  cacy for ADHD. However, despite greater 
than 50% DAT occupancy by d-MPH when administered 
intravenously or orally, the reinforcing effects were not 
perceived by patients receiving oral d-MPH (Volkow et al 
2002). This phenomenon is possibly due to slower blockade 
of DAT by oral d-MPH and may explain why intravenous 
injection of MPH may lead to addiction. Finally, there is 
no inter-conversion between the enantiomers after oral 
administration of pure d- and l-MPH separately (Volkow 
et al 2002).
The recent in vitro binding study of Markowitz et al 
(2005) found that d-MPH exhibited prominent effects at the 
norepinephrine transporter site, even exceeding the activity at 
the DAT. The result demonstrated that afﬁ  nity for catechol-
aminergic sites largely resides in the d-isomer.
Toxicology studies in animals
Animal toxicology studies showed that the toxicity of 
d-MPH and d,l-MPH were comparable at equimolar doses 
(Teo et al 2002). A recent comparative study assessing 
the acute behavioral toxicity of d-MPH, l-MPH, and 
d,l-MPH in rats has revealed that females were more 
sensitive than males to some toxic behavioral effects of 
the l-isomer and d,l-MPH (racemic), suggesting a pos-
sible sex difference in sensitivity (Teo et al 2003d). In 
related studies, increased incidence of dilated pupils and 
vocalization was found with d,l-MPH compared with the 
pure d-MPH given at half the dose (Teo et al 2002). In the 
same study, no other signiﬁ  cant toxic effects were found in 
perinatal or postnatal rats at a dose 25 times the maximum 
daily human therapeutic dose (Teo et al 2002). Another 
toxicology study in beagle dogs demonstrated that only 
minimal reversible toxicity such as reduced appetite and 
weight loss were found in male and female dogs receiving 
10 mg/kg of d-MPH and 20 mg/kg of d,l-MPH for 90 days 
(Teo et al 2003c).
Neither d-MPH nor d,l-MPH were found to be carci-
nogenic or clastogenic in either in vitro or in vivo stud-
ies, although very high oral doses of the l-MPH produce 
behavioral, and even lethal, effects in mice (Teo et al 
2003a). The authors believed that d-MPH and d,l-MPH 
do not present carcinogenic risk to humans. Animal stud-
ies in rats and rabbits also suggested that d-MPH and 
d,l-MPH were not teratogenic (Teo et al 2003b). The same 
study suggested that some negative behaviors in pregnant 
animals may be attributed to l-MPH because inclusion 
of the l-isomer, when comparing d,l-MPH and d-MPH at 
half the dose, resulted in repetitive pawing, dilated pupil, 
and aggressive behavior. A recent study, using PET and 
MicroPET to trace orally administered, as well as radiola-
beled d- and l-MPH, in the brain of baboons and rats, sug-
gested that l-MPH may not be pharmacologically active. 
Additionally, l-MPH might contribute to the behavioral 
and side-effect proﬁ  les of d,l-MPH during the treatment 
of ADHD (Ding et al 2004).
Immediate-release and extended-
release form of d-MPH
The immediate-release (IR) d-MPH product is deemed to 
provide effective management of ADHD at half the dose of 
racemic MPH products and was shown to be effective and 
well tolerated in clinical trials (Swanson et al 2002; Arnold 
et al 2004; Quinn et al 2004; Wigal et al 2004). An initial 
pharmacokinetic study showed that after an oral dose of d-
MPH, plasma d-MPH concentration increased rapidly, reach-
ing maximum levels at 1–1.5 hours post-dose in fasting states. 
Plasma pharmacokinetics of d-MPH were similar to d,l-MPH 
given the equimolar amounts of d-MPH. The mean plasma 
elimination half-life for d-MPH is approximately 2.2 hours 
(Anonymous 2002). However, recent studies, including one 
post hoc analysis (Weiss et al 2004), one open-labeled (Silva 
et al 2004), and three placebo-controlled clinical studies 
(Arnold et al 2004; Quinn et al 2004; Wigal et al 2004) in 
children with ADHD, suggested that IR d-MPH may pro-
duce a longer duration of therapeutic action (  6 hours) 
which cannot be explained solely on the basis of the agent’s 
pharmacokinetics.Neuropsychiatric Disease and Treatment 2006:2(4) 471
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Some authors have postulated that the need for a 
midday dose for IR MPH products may erode social 
functioning and sometimes the self-esteem of children 
with ADHD. Thus, an extended-release form of d-MPH 
(d-MPH-XR) was designed, known as Focalin XR®, and 
approved by FDA for clinical use in May 2005. This prod-
uct is a modiﬁ  ed release capsule formulation of d-MPH 
speciﬁ  cally engineered to deliver a bimodal (biphasic) 
release of d-MPH that mimics a twice daily d-MPH dosing 
(ie, two distinct peaks approximately 4 hours apart). The 
d-MPH-XR product uses the same proprietary SODAS 
(Spheroidal Oral Drug Absorption System) technology as 
one of the racemic MPH products (Ritalin-LA®) currently 
on the market. For each of these products, capsules are 
ﬁ  lled with a mixture of 50% immediate-release beads and 
50% enteric-coated, delayed-release beads, thus providing 
immediate release and a second delayed-release compo-
nent. After administration of d-MPH-XR, the ﬁ  rst peak 
concentration (Cmax1) of d-MPH occurs on average after 
1.5 hours (typical range 1–4 hours). The mean time to the 
inter-peak minimum is slightly shorter, and time to the 
second peak (tmax2) is slightly longer for d-MPH- XR given 
once daily (about 6.5 hours, range 4.5–7 hours) compared 
with the IR d-MPH given in two doses 4 hours apart. The 
d-MPH-XR product given once daily exhibits a lower sec-
ond peak concentration (Cmax2), higher inter-peak minimum 
concentrations, and fewer peak and trough ﬂ  uctuations 
than the IR form of the agent, given in two doses 4 hours 
apart. The area under the plasma concentration-time curve 
(AUC) after administration of d-MPH-XR given once daily 
is equivalent to the same total dose of IR d-MPH tablets 
given in two doses 4 hours apart (Novartis Pharmaceuticals 
Corporation 2005).
The clinical efﬁ  cacy as well as safety of d-MPH-XR 
in treating children with ADHD was demonstrated in a 
randomized, double-blind, placebo-controlled clinical trial 
(Greenhill et al 2005). In this study, ﬂ  exible dosing schedules 
of between 5 and 30 mg of d-MPH-XR were administered 
once daily over a 7-week period. Greenhill et al (2005) 
reported that d-MPH-XR was associated with signiﬁ  cantly 
improved attention and behavior in children with ADHD. 
Silva et al (2005, 2006), in two separate studies, demon-
strated that the therapeutic effect signiﬁ  cantly differentiated 
from placebo during each time point of the 12-hour labora-
tory classroom studies. Both of these studies employed a 
double-blind, placebo-controlled, crossover design. The 
sample sizes were slightly more than 50 patients in each 
trial; all subjects satisﬁ  ed DSM-IV criteria for ADHD. 
The children ranged in age between 6 and 12 years. In both 
studies, the d-MPH-XR dose administered was 20 mg/day. 
In the two studies, Swanson, Kotkin, Agler, M-Flynn, and 
Pelham (SKAMP) scales and math tests were administered. 
Signiﬁ  cant differences were observed across all measures and 
in each of the subscales at each of the time points studied. 
Another noteworthy observation is related to the elapsed 
time at which efﬁ  cacy was ﬁ  rst detected. In the Silva et al 
(2005) study signiﬁ  cant differences were noted at the ﬁ  rst 
time point measured, which was half an hour after medica-
tion administration.
Conclusions
Based on the information we have reviewed it seems that 
d-MPH is a useful agent in the treatment of ADHD. Fur-
thermore, it should be noted it is the only MPH product 
approved for the treatment of this disorder in adults. The 
literature reviewed identiﬁ  ed that there are meaningful dif-
ferences in the clinical efﬁ  cacy and pharmacokinetic proﬁ  le 
between the d- and l-isomers of MPH. When comparing the 
single isomer with the racemic compound, a consistently 
noted difference across studies is that d-MPH has a longer 
duration of action than d,l-MPH. This has been reported 
with both immediate-release and extended-release prepa-
rations. Further study is required to more fully understand 
the side-effect differences between the d-isomer and its 
racemic counterpart.
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